Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ADARx Pharmaceuticals
Biotech
ADARx scores upsized $446M IPO, while City maps out Nasdaq plans
ADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public listing.
James Waldron
Sep 25, 2026 2:46am
AbbVie-backed ADARx plans IPO to fund array of siRNA med trials
Sep 6, 2026 2:25pm
Tang takes over Aurinia after FDA brouhaha—Chutes & Ladders
Mar 27, 2026 11:05am
Moderna CMO steps down in leadership mix-up—Chutes & Ladders
Feb 6, 2026 8:30am
2 ex-Moderna leaders unveil $325M inaugural VC fund
Oct 9, 2025 3:09pm
AbbVie tosses ADARx $335M for siRNA options deal
May 14, 2025 9:00am
